Given that activating FGFR2 mutations are exceptionally rare in ICC, future tumor-agnostic investigations focusing on FGFR site mutations harbor the potential to expand the applicability of FGFR inhibitors. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.